{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"No Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Partial response (PR) defined as at least \\> 50 % reduction of serum monoclonal IgM concentration determined by protein electrophoresis, \\> 50% decrease in adenopathy / organomegaly on physical examination or on CT scan, and no new symptoms or signs of active disease. Complete response (CR) defined as a disappearance of serum and urine monoclonal protein determined by immunofixation, absence of malignant cells in bone marrow determined by histologic evaluation, resolution of adenopathy/organomegaly (confirmed by computed tomography \\[CT\\] scan), and no signs or symptoms attributable to WM. Stable disease defined as neither grown nor shrunk; the amount of disease has not changed.Participants will be followed for \\< 6 months after receiving bortezomib/rituximab or rituximab-modified hyper-CVAD to be considered unresponsive to therapy in accordance with the guidelines of the Consensus Panel of the Third International Workshop on Waldenstrom's Macroglobulinemia.","groups":[{"description":"Bortezomib 1.6 mg/m\\^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m\\^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).\n\nBortezomib: 1.6 mg/m\\^2 IV Weekly on Days 1, 8, 15 and 22.\n\nRituximab: 375 mg/m\\^2 IV on Day 8 and 22.\n\nValacyclovir: 500 mg orally daily (or acyclovir 200 mg orally twice daily)","id":"OG000","title":"All Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 subject didn't complete 2 cycles of therapy and isn't evaluable for response","reportingStatus":"POSTED","timeFrame":"After 2 (35 day) cycles of treatment","title":"Response Rate After 2 Cycles of Treatment With Bortezomib and Rituximab","type":"PRIMARY","unitOfMeasure":"Participants"}